PT - JOURNAL ARTICLE AU - Tan, Qi AU - Jin, Yang TI - Ostavimir is ineffective against COVID-19: in silico assessment, in vitro and retrospective study AID - 10.1101/2020.05.15.20102392 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.15.20102392 4099 - http://medrxiv.org/content/early/2020/05/20/2020.05.15.20102392.short 4100 - http://medrxiv.org/content/early/2020/05/20/2020.05.15.20102392.full AB - As a neuraminidase inhibitor, oseltamivir has effectively combated the pandemic influenza A and B, so it is a first-line commonly used antiviral drug, especially in primary hospitals. At the same time, oseltamivir, as an over-the-counter drug, is also a popular antiviral drug. As healthcare workers fighting against coronavirus disease 2019 (COVID-19), we have found that many patients experiencing discomfort or considered to be infected with a virus take oseltamivir. From severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 to middle east respiratory syndrome coronavirus (MERS-CoV) in 2012, and now the current COVID-19 epidemic, there is not plenty of evidence showing that oseltamivir is effective against coronavirus. Still, there is also no sufficient evidence to refute its ineffectiveness. We cannot predict whether there will be a pandemic of respiratory coronavirus in the future, so we hope to initiate such research and preliminarily explore whether oseltamivir is effective for COVID-19, which can better guide healthcare workers in the selection of appropriate antiviral drugs in the face of coronavirus epidemics. If oseltamivir is effective, then a wide promotion of its application often can achieve a double effect with half the effort. If it is not effective, then considering the side effects of oseltamivir, it is not necessary to use unreasonable drugs that will not slow the progression of the disease but can cause adverse reactions. We found that oseltamivir isn’t suitable for fighting against COVID-19 through the method of computer aided drug design and in vitro study and retrospective case study. Meanwhile it was high-occurrence seasons for the influenza, COVID-19 should be highly suspected in patients who didn’t benefit from oseltamivir. We hope that the result of our study could be shared with the frontline physicians in fighting against COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis paper was supported by Novel coronavirus pneumonia emergency project, China (no.2020YFC084430), State Key Laboratory of Drug Research, China (no. 2019ZX09301001) and the National Natural Science Foundation of China (no.82041018, no. 81770096 and no. 81700091).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.